



(51) International Patent Classification:

A61K 51/08 (2006.01) C07K 14/31 (2006.01)
A61K 101/02 (2006.01)

(21) International Application Number:

PCT/US2011/065777

(22) International Filing Date:

19 December 2011 (19.12.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12/975,425	22 December 2010 (22.12.2010)	US
61/438,297	1 February 2011 (01.02.2011)	US
61/510,520	22 July 2011 (22.07.2011)	US
61/541,287	30 September 2011 (30.09.2011)	US

(71) Applicants (for all designated States except US): **GENERAL ELECTRIC COMPANY** [US/US]; One River Road, Schenectady, NY 12345 (US). **AFFIBODY AB** [SE/SE]; Lindhagensgatan 133, S-112 51 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SYUD, Faisal** [BD/US]; 13 Brittany Oaks, Clifton Park, NY 12065 (US). **LEE, Brian Duh-Lan** [US/US]; General Electric Company, One Research Circle, Bldg. K1-3A59, Niskayuna, NY 12345 (US). **ZHANG, Rong** [CN/US]; General Electric Company, One Research Circle, Bldg. K1-3A59, Niskayuna, NY 12345 (US). **IVESON, Peter** [GB/GB]; GE Healthcare Limited, The Grove Centre, White Lion Road, Amersham Buckinghamshire HP7 9LL (GB). **SCHAFFER, Paul** [CA/CA]; Nuclear Medicine Division, Triumf, 4004 Westbrook Mall, Vancouver, V6T 2A3 (CA). **ERIKSSON, Tove** [SE/SE]; Sten Stures vag 69, S-131 47 Nacka (SE). **GUNNERIUSSON, Elin** [SE/SE]; Algovagen 21, S-133 36 Saltsjobaden (SE). **FREJD, Fredrik**

[SE/SE]; Jacob Westingatan 6, S-112 20 Stockholm (SE). **ABRAHMSEN, Lars** [SE/SE]; Vereliusvagen 17, S-168 58 Bromma (SE). **FELDWISCH, Joachim** [DE/SE]; Korallvagen16, S-135 42 Tyreso (SE). **HERNE, Nina** [SE/SE]; Nybodaringen 64, S-117 62 Stockholm (SE). **LENDEL, Christofer** [SE/SE]; Glavagatan 3, S-123 71 Farsta (SE).

(74) Agents: **LEE, Christine** et al.; GE Healthcare, Inc., 101 Carnegie Center, Princeton, NJ 08540 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: RADIOLABELLED HER2 BINDING PEPTIDES

(57) Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.



WO 2012/096760 A1